[Heart and Kidneys]

Overview

Journal Internist (Berl)

Specialty General Medicine

Date 2010 Jun 4

PMID 20521018

Authors

D Kiski

H Reinecke

Affiliations

Soon will be listed here.

Abstract

There is strong interaction between heart and kidneys in human beings. Both organs work together in many regulation mechanisms. Thus, heart failure leads in many cases to renal failure due to hemodynamic or hormonal feed-back mechanisms. Vice versa, chronic kidney disease turned out as a major and independent cardiovascular risk factor. Patients who suffer from both heart disease and chronic kidney disease are threatened from a very high morbidity and mortality. Moreover, the number of affected patients has doubled every 8-10 years--a dramatic trend which is ongoing. In many patients suffering from heart and chronic kidney disease, an under-use of cardiologic diagnostics as well as therapies has to be observed due to fears about adverse effects, which further enhances their worse prognosis.

References

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

de Jager D, Grootendorst D, Jager K, van Dijk P, Tomas L, Ansell D . Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009; 302(16):1782-9. DOI: 10.1001/jama.2009.1488. View

Go A, Chertow G, Fan D, McCulloch C, Hsu C . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13):1296-305. DOI: 10.1056/NEJMoa041031. View

Meyer A, Bunzemeier H, Hausberg M, Walter M, Roeder N, Breithardt G . Impact of different stages of chronic kidney disease on in-hospital costs in patients with coronary heart disease. Nephrol Dial Transplant. 2007; 23(6):1955-60. DOI: 10.1093/ndt/gfm879. View

Gradaus F, Ivens K, Peters A, Heering P, Schoebel F, Grabensee B . Angiographic progression of coronary artery disease in patients with end-stage renal disease. Nephrol Dial Transplant. 2001; 16(6):1198-202. DOI: 10.1093/ndt/16.6.1198. View

Reinecke H, Brand E, Mesters R, Schabitz W, Fisher M, Pavenstadt H . Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2008; 20(4):705-11. DOI: 10.1681/ASN.2007111207. View

Aoki J, Ong A, Hoye A, van Herwerden L, Sousa J, Jatene A . Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. Eur Heart J. 2005; 26(15):1488-93. DOI: 10.1093/eurheartj/ehi288. View

Snyder J, Foley R, Collins A . Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008; 53(2):218-28. PMC: 2664624. DOI: 10.1053/j.ajkd.2008.07.034. View

Pfeffer M, Burdmann E, Chen C, Cooper M, de Zeeuw D, Eckardt K . A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009; 361(21):2019-32. DOI: 10.1056/NEJMoa0907845. View

10.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

11.

El Nahas A, Bello A . Chronic kidney disease: the global challenge. Lancet. 2005; 365(9456):331-40. DOI: 10.1016/S0140-6736(05)17789-7. View

12.

Fellstrom B, Jardine A, Schmieder R, Holdaas H, Bannister K, Beutler J . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14):1395-407. DOI: 10.1056/NEJMoa0810177. View

13.

Ronco C, McCullough P, Anker S, Anand I, Aspromonte N, Bagshaw S . Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J. 2009; 31(6):703-11. PMC: 2838681. DOI: 10.1093/eurheartj/ehp507. View

14.

Hamer R, El Nahas A . The burden of chronic kidney disease. BMJ. 2006; 332(7541):563-4. PMC: 1397782. DOI: 10.1136/bmj.332.7541.563. View

15.

Collins A, Foley R, Gilbertson D, Chen S . The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol. 2009; 4 Suppl 1:S5-11. DOI: 10.2215/CJN.05980809. View

16.

Berger A, Duval S, Krumholz H . Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003; 42(2):201-8. DOI: 10.1016/s0735-1097(03)00572-2. View

17.

Levey A, Andreoli S, DuBose T, Provenzano R, Collins A . Chronic kidney disease: common, harmful, and treatable--World Kidney Day 2007. J Am Soc Nephrol. 2007; 18(2):374-8. DOI: 10.1681/ASN.2006121305. View

18.

Hemmelgarn B, Southern D, Culleton B, Mitchell L, Knudtson M, Ghali W . Survival after coronary revascularization among patients with kidney disease. Circulation. 2004; 110(14):1890-5. DOI: 10.1161/01.CIR.0000143629.55725.D9. View

19.

Shankar A, Klein R, Klein B . The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006; 164(3):263-71. DOI: 10.1093/aje/kwj173. View

20.

Ivens K, Gradaus F, Heering P, Schoebel F, Klein M, Schulte H . Myocardial revascularization in patients with end-stage renal disease: comparison of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting. Int Urol Nephrol. 2002; 32(4):717-23. DOI: 10.1023/a:1015067611958. View